Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
Status:
Withdrawn
Trial end date:
2018-09-02
Target enrollment:
Participant gender:
Summary
This phase I/II pilot trial seeks to demonstrate that prolonged administration of Campath-1H
without prior marrow or stem cell harvesting can result in immunoablation similar to that
achieved by hematopoietic stem cell transplantation (HSCT) from either bone marrow or
peripheral blood stem cell sources in children and adolescents with severe treatment
refractory systemic sclerosis (SSc).